Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Absence of the Cancer-associated Factor with a Molecular Weight of 60,000 from the Plasma of Patients with a Spectrum of Nonneoplastic Conditions

Absence of the Cancer-associated Factor with a Molecular Weight of 60,000 from the Plasma of... We demonstrated previously (Cancer Res., 42: 4964–4969, 1982) that a tumor-associated factor was consistently present in the plasma of over 100 human cancer patients with tumors at 31 different sites. The plasma of healthy controls had very low activity in the biochemical assay. In the present study, we show by a combination of molecular sieving and assay of nuclear RNA transport that the tumor-associated factor, which has a molecular weight of 60,000, is undetectable in the plasma of healthy adults. The low activity reported earlier is due to three normal cell factors of markedly different molecular weight. Furthermore, the tumor factor is shown to be absent from the plasma of male and female patients hospitalized for a variety of nonmalignant surgical conditions. Only the plasma from patients who were pregnant, suffered from chronic renal failure, or had recent myocardial infarction gave false positives in the biochemical assay. However, in these cases, the activity was due to an increase in the normal tissue-associated factors and not to the appearance of the M r 60,000 tumor-associated factor. The factor is present in amniotic fluid, confirming that it is a fetal factor which does not cross the placental barrier. Thus, it may be classified as an oncofetal factor. All four factors found in the plasma were identified in the cytosol from a human tumor. In summary, the tumor-associated factor appears to be tumor specific and can be unambiguously identified by bioassay of the plasma factors eluting from Sepharose CL-6 B columns in the M r 60,000 region. It can also be identified by examination of sodium dodecyl sulfate:polyacrylamide gel electrophoretograms of the appropriate Sepharose CL-6 B fractions after removal of albumin. 1 Supported by Grants CA 30627 and P-30-CA-16058-09 from the NIH, Department of Health and Human Services. 2 To whom requests for reprints should be addressed. 3 Permanent address: Institute of Oncology, Department of Tumor Biology, 44-100 Gliwice, Poland. 4 Recipient of Grant CA 30627 from the NIH. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Research American Association of Cancer Research

Absence of the Cancer-associated Factor with a Molecular Weight of 60,000 from the Plasma of Patients with a Spectrum of Nonneoplastic Conditions

Absence of the Cancer-associated Factor with a Molecular Weight of 60,000 from the Plasma of Patients with a Spectrum of Nonneoplastic Conditions

Cancer Research , Volume 44 (1): 401 – Jan 1, 1984

Abstract

We demonstrated previously (Cancer Res., 42: 4964–4969, 1982) that a tumor-associated factor was consistently present in the plasma of over 100 human cancer patients with tumors at 31 different sites. The plasma of healthy controls had very low activity in the biochemical assay. In the present study, we show by a combination of molecular sieving and assay of nuclear RNA transport that the tumor-associated factor, which has a molecular weight of 60,000, is undetectable in the plasma of healthy adults. The low activity reported earlier is due to three normal cell factors of markedly different molecular weight. Furthermore, the tumor factor is shown to be absent from the plasma of male and female patients hospitalized for a variety of nonmalignant surgical conditions. Only the plasma from patients who were pregnant, suffered from chronic renal failure, or had recent myocardial infarction gave false positives in the biochemical assay. However, in these cases, the activity was due to an increase in the normal tissue-associated factors and not to the appearance of the M r 60,000 tumor-associated factor. The factor is present in amniotic fluid, confirming that it is a fetal factor which does not cross the placental barrier. Thus, it may be classified as an oncofetal factor. All four factors found in the plasma were identified in the cytosol from a human tumor. In summary, the tumor-associated factor appears to be tumor specific and can be unambiguously identified by bioassay of the plasma factors eluting from Sepharose CL-6 B columns in the M r 60,000 region. It can also be identified by examination of sodium dodecyl sulfate:polyacrylamide gel electrophoretograms of the appropriate Sepharose CL-6 B fractions after removal of albumin. 1 Supported by Grants CA 30627 and P-30-CA-16058-09 from the NIH, Department of Health and Human Services. 2 To whom requests for reprints should be addressed. 3 Permanent address: Institute of Oncology, Department of Tumor Biology, 44-100 Gliwice, Poland. 4 Recipient of Grant CA 30627 from the NIH.

Loading next page...
 
/lp/american-association-of-cancer-research/absence-of-the-cancer-associated-factor-with-a-molecular-weight-of-60-fW2DNM1ov6

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Association of Cancer Research
Copyright
Copyright © 1984 by the American Association for Cancer Research.
ISSN
0008-5472
Publisher site

Abstract

We demonstrated previously (Cancer Res., 42: 4964–4969, 1982) that a tumor-associated factor was consistently present in the plasma of over 100 human cancer patients with tumors at 31 different sites. The plasma of healthy controls had very low activity in the biochemical assay. In the present study, we show by a combination of molecular sieving and assay of nuclear RNA transport that the tumor-associated factor, which has a molecular weight of 60,000, is undetectable in the plasma of healthy adults. The low activity reported earlier is due to three normal cell factors of markedly different molecular weight. Furthermore, the tumor factor is shown to be absent from the plasma of male and female patients hospitalized for a variety of nonmalignant surgical conditions. Only the plasma from patients who were pregnant, suffered from chronic renal failure, or had recent myocardial infarction gave false positives in the biochemical assay. However, in these cases, the activity was due to an increase in the normal tissue-associated factors and not to the appearance of the M r 60,000 tumor-associated factor. The factor is present in amniotic fluid, confirming that it is a fetal factor which does not cross the placental barrier. Thus, it may be classified as an oncofetal factor. All four factors found in the plasma were identified in the cytosol from a human tumor. In summary, the tumor-associated factor appears to be tumor specific and can be unambiguously identified by bioassay of the plasma factors eluting from Sepharose CL-6 B columns in the M r 60,000 region. It can also be identified by examination of sodium dodecyl sulfate:polyacrylamide gel electrophoretograms of the appropriate Sepharose CL-6 B fractions after removal of albumin. 1 Supported by Grants CA 30627 and P-30-CA-16058-09 from the NIH, Department of Health and Human Services. 2 To whom requests for reprints should be addressed. 3 Permanent address: Institute of Oncology, Department of Tumor Biology, 44-100 Gliwice, Poland. 4 Recipient of Grant CA 30627 from the NIH.

Journal

Cancer ResearchAmerican Association of Cancer Research

Published: Jan 1, 1984

There are no references for this article.